By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Response today announced a joint research and development deal with Scripps Genomic Medicine targeting oncology and cardiovascular disease.

The deal calls for Molecular Response to fund up to two discovery programs in the two indications. In return, Scripps will grant the San Diego-based firm exclusive intellectual property rights.

Further financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.